Quan Capital Management is a venture capital firm that invests in healthcare, pharmaceutical, and biotech startups. The Company is based in China, but makes investments globally.
Investment Type: Venture Capital
Portfolio 3
| Date | Name | Website | Total Raised | Location |
| 26.03.2026 | Pinnacle M... | pinnaclemedicines.com | $89M | United Sta... |
| 22.09.2025 | Avenzo The... | avenzotx.com | $210M | United Sta... |
| 24.07.2023 | Crescendo ... | crescendobiologics.com | $133.79M | United Kin... |
Mentions in press and media 12
| Date | Title | Description |
| 06.05.2026 | Windward Bio Announces $165 Million Crossover Financing To Advance Long-Acting Immunology Pipeline | Windward Bio, a private, clinical-stage biotechnology company based in Basel, Switzerland, has announced an upsized $165 million crossover financing led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, S... |
| 30.03.2026 | Pinnacle Medicines Secures $89M Series B: Oral Peptides Advance Clinical Pipeline with AI Power | Pinnacle Medicines, a Doylestown, PA biotech, closed an oversubscribed $89 million Series B funding round. This significant capital injection accelerates its oral peptide therapeutics pipeline. The company targets immunology and cardiometab... |
| 29.03.2026 | Pinnacle Medicines: $89 Million Series B Raised For Oral Peptide Therapeutics Development | Pinnacle Medicines, a biotechnology company focused on oral peptide therapeutics, announced it has closed an oversubscribed $89 million Series B financing round to advance its pipeline into clinical trials. The round was co-led by LAV and F... |
| 26.03.2026 | Pinnacle Medicines Raises $89M in Series B Funding | Pinnacle Medicines, a Doylestown, PA-based biotechnology company developing oral peptide therapeutics, raised $89M in Series B funding. The round was led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA... |
| 03.10.2025 | Avenzo Therapeutics Secures $60 Million Series B to Advance Oncology Breakthroughs | Avenzo Therapeutics secured $60 million in Series B funding. This propels their oncology pipeline. The San Diego biotech now totals $446 million raised. OrbiMed and SR One led the round. New investor Longwood Fund joined. Key existing backe... |
| 23.09.2025 | Avenzo: $60 Million Series B Secured For Developing Oncology Therapies | Avenzo Therapeutics, a biotechnology company focused on developing new cancer treatments, has announced the closing of a $60 million Series B funding round. This latest investment follows a previous $386 million raised through its Series A ... |
| 22.09.2025 | Avenzo Therapeutics Raised $60M in Series B Funding | Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies, raised $60M in Series B funding. The round was led by OrbiMed and SR One, with participation from new investor Longwood Fund,... |
| 22.07.2025 | Lumotive Receives Investment from Amazon and ITHCA | Lumotive, a Redmond, WA-based programmable optical semiconductor technology company, received an investment from Amazon and Ithca. The amount of the deal was not disclosed. The company intends to use the funds to expand operations and its d... |
| 14.01.2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
| 13.01.2025 | Windward Bio launches with $200 million Series A financing round | Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the... |
Show more